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a  b  s  t  r  a  c  t
In the poultry  industry,  infections  with  avian  inﬂuenza  virus  (AIV)  can  result  in signiﬁcant
economic  losses.  The  risk  and  the  size  of  an outbreak  might  be restricted  by  vaccination  of
poultry.  A  vaccine  that  would  be  used  for rapid intervention  during  an  outbreak  should  be
safe  to use,  highly  effective  after  a single  administration  and  be  suitable  for mass  application.
A vaccine  that  could  be  applied  by spray  or aerosol  would  be  suitable  for mass  application,
but  respiratory  applied  inactivated  inﬂuenza  is poorly  immunogenic  and  needs  to be  adju-
vanted. We  chose  aluminum  OH,  chitosan,  cholera  toxin  B subunit  (CT-B),  and  Stimune  as
adjuvant  for  an  aerosolized  vaccine  with  inactivated  H9N2.  Each  adjuvant  was  tested  in
two doses.  None  of  the  adjuvanted  vaccines  induced  AIV-speciﬁc  antibodies  after  single
vaccination,  measured  1 and  3 weeks  after  vaccination  by  aerosol,  in  contrast  to  the intra-
muscularly applied  vaccine.  The  aerosolized  vaccine  did  enter  the  chickens’  respiratory  tract
as  CT-B-speciﬁc  serum  antibodies  were  detected  after  1  week  in chickens  vaccinated  with
the  CT-B-adjuvanted  vaccine.  Chickens  showed  no adverse  effects  after  the aerosol  vacci-
nation  based  on  weight  gain  and clinical  signs.  The  failure  to  detect  AIV-speciﬁc  antibodies
might  be due  to  the concentration  of  the inactivated  virus.
© 2011 Elsevier B.V. All rights reserved.
Abbreviations: AIV, avian inﬂuenza virus; alum, aluminum OH; BPL,
beta-propiolactone; CT-B, cholera toxin B subunit; GM-1, ganglioside M-
1;  HAU, haemagglutinating units; i.n., intranasal; NDV, Newcastle disease
virus; RT, respiratory tract; WIV, whole inactivated virus; wpv, weeks post
vaccination.
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1. Introduction
In the poultry industry, infections with avian inﬂuenza
virus (AIV) can result in signiﬁcant economic losses. The
risk and the size of an outbreak of AIV could be restricted
by vaccination of poultry. Possible vaccination strategies
are rapid intervention (emergency vaccination of poultry
in the area around an outbreak), preventive vaccination
of speciﬁc categories of poultry that are more at risk for
a new introduction of AIV (e.g. free range layers in areas
with many wild ducks and geese), and general preventive
vaccinations of poultry in areas in which AIV is endemic.
A vaccine used for rapid intervention during an outbreak
should be safe, highly effective after a single administra-
0165-2427/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
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tion and be suitable for mass application. A vaccine that
could be applied by spray or aerosol would be suitable
for mass application, which is regularly performed for e.g.
infectious bronchitis virus (De Wit  et al., 2010), Newcas-
tle disease virus (NDV), avian metapneumovirus and most
Mycoplasma galliseptum vaccines (Ley, 2003). In the case
of AIV, aerosol vaccination using live virus is not desirable
because of its zoonotic potential and because of the risk for
virus reassortment. Mucosal vaccination via the respiratory
route has several advantages: it induces both local and sys-
temic immune responses (Atmar et al., 2007; Tseng et al.,
2009; Worrall et al., 2009), it could halt infection already
at portal of entry (Yoshikawa et al., 2004) and it is suitable
for mass application.
The respiratory tract (RT) mucosa constantly comes
into contact with inhaled Ag and in normal circumstances
these Ag do not provoke strong immune responses, but
induce a state of tolerance (Akbari et al., 2001) leading
to a tolerogenic environment in the RT. Intranasally (i.n.)
applied whole inactivated AIV (WIV) is poorly immuno-
genic (Hagenaars et al., 2008), as was also described in
chicken for i.n. applied WIV  (Worrall et al., 2009) and i.n.
applied inactivated NDV (Tseng et al., 2009). To enhance
the immunogenicity of WIV  it needs to be adjuvanted.
We chose aluminum (alum) OH, chitosan, cholera toxin
B subunit (CT-B), and Stimune as adjuvant for in an
aerosolized vaccine with inactivated H9N2. Alum adju-
vants are the most widely used adjuvants for human
vaccines (Lambrecht et al., 2009) and it is an effective
adjuvant in inﬂuenza vaccines in mice (Chang et al.,
2010) and chicken (Reemers et al., 2010). However, in
human inﬂuenza trials results are less consistent, with
an aluminum phosphate adjuvanted H9N2 WIV  i.m. vac-
cine being well tolerated and immunogenic (Nicholson
et al., 2009), while other groups found that H1N1 split
virus (detergent-disrupted virion) vaccine formulations
containing alum were less immunogenic than formula-
tions without adjuvant when given i.m. (Zhu et al., 2009).
Chitosan has shown promising results in i.n. split virus vac-
cines in mice (Bacon et al., 2000), split virus and protein
vaccines in human (Read et al., 2005; Sui et al., 2010a,b) and
a split virus vaccine in poultry (Worrall et al., 2009; Rauw
et al., 2010). It was previously shown that CT is an effec-
tive mucosal adjuvant in chicken (Vervelde et al., 1998),
but CT cannot be used in the ﬁeld because of its toxicity.
CT-B containing trace amounts of CT is an effective adju-
vant in i.n. delivered split virus vaccines in mice (Matsuo
et al., 2000), but because of the toxicity of CT and the mass
application as intended in the ﬁeld, we decided to use pure
CT-B. CT-B already showed protective effects in chickens
with an i.n. applied inactivated NDV vaccine (Takada and
Kida, 1996). Stimune, also known as Specol, has been used
successfully in an i.m. vaccine using soluble trimeric H5
protein in chicken (Cornelissen et al., 2010).
In this study, different adjuvants were tested in an
aerosolized vaccine using WIV  for use in a rapid inter-
vention strategy. None of the adjuvanted vaccines induced
AIV-speciﬁc Ab after a single vaccination, measured 1 and 3
weeks post vaccination (wpv) by aerosol, in contrast to the
i.m. applied vaccine. The aerosolized vaccine did enter the
chickens’ RT as CT-B-speciﬁc Ab were detected in serum
from 1 wpv  onwards. Chickens showed no adverse effects
on weight gain and no clinical signs after aerosol vaccina-
tion.
2. Materials and methods
2.1. Chickens
One-day-old speciﬁc pathogen free broiler chickens (a
crossbred of Hybro and Cobb) of both sexes (Animal Health
Service, Deventer, the Netherlands) were housed at the
Utrecht University animal facilities. Animals were housed
in groups on the ﬂoor with sawdust bedding and received
food and water ad libitum. Aerosol vaccination was per-
formed at Animal Health Service Deventer. In compliance
with Dutch law, all experiments were approved by the Ani-
mal  Experimental Committee of the Faculty of Veterinary
Medicine of Utrecht University, the Netherlands, in accor-
dance with the Dutch regulation on experimental animals.
2.2. Virus
H9N2 A/Chicken/Saudi Arabia/SP02525/3AAV/2000
(Animal Health Service, Deventer, the Netherlands) was
used for vaccination. The virus titer was 1.2 × 108 EID50/ml
or 405 haemagglutinating units (HAU)/ml. Before vaccina-
tion, the virus was inactivated using beta-propiolactone
(BPL; Acros organics). Brieﬂy, a 10% BPL solution was
prepared in a 125 mM sodium citrate and 150 mM sodium
chloride buffer and 10 l/ml was added to the virus.
Virus-BPL solution was then incubated for 24 h at 4 ◦C
under continuous stirring. Inactivation was  conﬁrmed by
inoculation in embryonated chicken eggs performed by
Animal Health Service Deventer.
2.3. Vaccines
Each adjuvant was  used in 2 doses: a low dose and a
high dose. Imject alum (Pierce) was  used 1:3 and 1:1 mixed
with WIV. Stimune (Prionics) was  mixed 1:2 and 1:1 for
i.m. vaccination, Stimune was mixed with WIV  according
to manufacturer’s instructions (5 parts Stimune and 4 parts
water phase). CT-B (Sigma) was  used at a concentration of
10 g/chicken and 50 g/chicken. Chitosan (Protasan UP CL
213; Novamatrix) was used as a 1.5% (w/v) and a 3% (w/v)
solution in sterile saline.
Chickens were vaccinated with approximately 75 HAU
WIV. To calculate the amount of virus needed, the breath-
ing volume was  estimated at 44 l/kg body weight per hour
(Fedde et al., 1998) and the volume of the isolator was
1.38 m3. The i.m. control group was vaccinated with 700 l
containing 75 HAU WIV  adjuvanted with Stimune.
2.4. Experimental set-up
Ninety-ﬁve three-week-old SPF broilers were random-
ized into 9 groups of 10 chickens and one control group of 5
chickens. Group 1 was aerosol-vaccinated with WIV  only;
groups 2 and 3 were aerosolized with alum-adjuvanted
vaccine in a low and high dose respectively; groups 4 and
5 were treated with chitosan-adjuvanted vaccine in a low
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and high dose; groups 6 and 7 were treated with the CT-
B-adjuvanted vaccine in low and high dose; groups 8 and
9 were aerosolized with the Stimune-adjuvanted vaccine
and group 10 was i.m. vaccinated with Stimune-adjuvanted
vaccine.
At the age of 3 weeks chickens were vaccinated by
aerosol. Animals were vaccinated in groups in isolators
(Beyer & Eggelaar) with a volume of 1.38 m3 (1.94 m long,
0.75 m wide and 0.95 m high). The vaccine was aerosolized
using a Walther Pilot I spray-head with 0.5 mm nozzle
(Walther Spritz- und Lackiersysteme), as described previ-
ously (Corbanie et al., 2008). After aerosolizing the vaccine,
chickens were left for 1 h in the isolator to inhale the vac-
cine. To check whether any of the aerosolized vaccines had
adverse effects, chickens were weighed weekly and were
checked for adverse effects on eyes and RT right after vac-
cination and in the week following vaccination. Blood was
collected before and 1 and 3 wpv and tracheal swabs were
taken 3 wpv. Chickens were killed 3 wpv.
2.5. Tracheal swabs
Swabs were put in 350 l PBS and mixed for 1 h at room
temperature to elute tracheal swab content. Swabs ﬂuid
was used for ELISA.
2.6. Avian inﬂuenza virus ELISA
IDEXX FlockChek Avian Inﬂuenza MultiS-Screen Ab
Test Kit (IDEXX) was used according to manufacturer’s
instructions. This ELISA is based on a competitive blocking
approach, the speciﬁc sample antibodies block the enzyme-
labeled, speciﬁc antibody in the conjugate. The addition of
an enzyme substrate-chromogen reagent causes color to
develop. This color is inversely proportional to the amount
of bound sample antibody. The more antibodies present in
the sample, the less color development in the test wells.
Sample/negative (S/N) ratio was calculated as follows: S/N
ratio = sample absorbance/negative control absorbance.
AIV-speciﬁc Ab were determined in serum and in
tracheal swab samples. Serum samples were diluted
according to manufacturer’s instructions. Tracheal swab
elutes were used without diluting.
2.7. CT-B antibody ELISA
To detect CT-B-speciﬁc Ab, a ganglioside M (GM)-1
ELISA was performed as described previously by Stok et
al. (1994).  Brieﬂy, high bind microplates (Corning) were
coated with 2 g/ml GM-1 (Sigma) at 4 ◦C overnight. Then
0.2 g/well CT-B (Sigma) was added and plates were incu-
bated for 1 h at room temperature. Serum was added
starting at a dilution of 1:50 and 1:1 serially diluted
to 1:6400 and incubated for 1 h at 37 ◦C. Horseradish
peroxidase-labeled goat-anti chicken IgG (H + L; Southern
Biotech) was added and plates were incubated for 1 h at
room temperature. Plates were developed using one-step
ultra TMB  (Pierce). Color development was stopped using
1 M H2SO4 and extinction was measured at 450 nm.
3. Results and discussion
In this study, inactivated AIV antigen with different
adjuvants was  tested in an aerosolized vaccine for use
in a rapid intervention strategy. A vaccine used for rapid
intervention vaccination strategies is aimed at stopping
an ongoing outbreak. It should therefore induce a rapid
protection, ideally after a single vaccination by a mass
application method to be effective in the ﬁeld situation.
Aerosol vaccinations were performed in an isolator, using
a Walther Pilot I spray-head. This set-up was  used in a pre-
vious experiment to aerosolize NDV (Corbanie et al., 2008)
and the spray-head was used previously to aerosolize ﬂu-
orescent microspheres (Corbanie et al., 2006). It was  found
that using this set-up the concentration of NDV in the iso-
lator did not decrease when measured up until 20 min  after
nebulization (Corbanie et al., 2008) and ﬂuorescent micro-
spheres were present throughout the respiratory tract,
including air sacs, at 20 min  after administration (Corbanie
et al., 2006). Furthermore, in a previous experiment we per-
formed aerosol inoculation with live H9N2 AIV (Reemers
et al., 2009). In another study chickens were inoculated
with virus via the intratracheal route and found similar
immune responses and similar kinetics of the responses
(Rebel et al., 2011).
Chickens were aerosol-vaccinated at 3 weeks of age
with H9N2 WIV  adjuvanted with either alum, chitosan, CT-
B or Stimune. To determine if the adjuvants had any adverse
effects on weight gain of the chickens, birds were weighed
weekly. To adjust for growth differences between the sexes,
we set the pre-vaccination body weight (day 19) at 100%
for each individual chicken and used this to calculate rel-
ative body weights. We  found no signiﬁcant differences in
relative body weight between any of the treatment groups
(data not shown). Furthermore, we  did not observe any res-
piratory or eye problems right after vaccination and in the
weeks following vaccination. The vaccines were therefore
safe to use.
From previous experiments using an i.m. applied vac-
cine, it was  determined that 42–128 HAU were needed
for an efﬁcient protection against a high-pathogenic H7N7
infection (Maas et al., 2009). In our experiments, chickens
were vaccinated with approximately 75 HAU by aerosol.
Chickens were bled before and 1 and 3 wpv  to detect AIV-
speciﬁc serum Ab after the vaccination.
The presence of AIV-speciﬁc Ab in serum at 1 and
3 wpv  was determined using a well validated ELISA. In
this commercial ELISA, the samples containing AIV-speciﬁc
antibodies have a sample/negative (S/N) ratio <0.5. Pre-
vaccination, no AIV-speciﬁc Ab were present in serum.
From 1 wpv, AIV-speciﬁc serum Ab were detected in the
i.m. vaccinated group, but not in any of the aerosol-
vaccinated animals (Fig. 1).
Primary i.n. vaccination in chicken with 100 HAU split
H5N1 virus + sialidase and 0.5% (w/v) chitosan already
induced mucosal AIV-speciﬁc IgA responses at 1 wpv  as
determined in tracheal swab elutes (Worrall et al., 2009).
When the antigen was  given with chitosan alone, AIV-
speciﬁc IgA responses were lower and IgA was  not detected
at all time points (Worrall et al., 2009). When chickens
were vaccinated at 1 day of age with replication-competent
146 E.D. de Geus et al. / Veterinary Immunology and Immunopathology 143 (2011) 143– 147
Fig. 1. AIV-speciﬁc Ab in serum of aerosol-vaccinated chickens. Presence of AIV-speciﬁc Ab in serum was determined pre-vaccination, 1 wpv and 3 wpv
using the IDEXX multispecies AIV antibody ELISA. Data are shown as mean S/N ratio + SEM. AIV-speciﬁc serum antibodies are detected in samples with S/N
ratios  <0.5. *P < 0.05 for S/N ratio when compared to WIV  only.
adenovirus-free AIV H7 vaccine via coarse spray, no HI
titers were detected in serum, however AIV-speciﬁc IgA
was detected in tears at day 10 post vaccination (Toro
et al., 2010). To test whether in our experiment Ab were
locally induced following aerosol vaccination, AIV-speciﬁc
Ab were determined in tracheal swab elutes. None of the
samples contained detectable levels of inﬂuenza-speciﬁc
Ab (data not shown).
To test if the aerosolized vaccine had entered the RT and
had induced immune responses, a CT-B antibody ELISA was
performed using sera of chickens vaccinated with CT-B-
adjuvanted vaccines. Pre-vaccination no CT-B-speciﬁc Ab
were detected. When the low dose of CT-B (10 g/chicken)
was given, CT-B-speciﬁc Ab were detected at 3 wpv. How-
ever, the high dose CT-B (50 g/chicken) already induced
CT-B-speciﬁc Ab at 1 wpv  and Ab titers were increased at
3 wpv. Vaccination with the high dose CT-B signiﬁcantly
increased the titer of CT-B speciﬁc Ab as compared to the
low dose of CT-B (Fig. 2).
In summary, although the aerosolized vaccines did enter
the chicken RTs, either the dose of inﬂuenza virus used
was insufﬁcient or a booster vaccination would be needed
in order to induce detectable levels of Ab. It has been
reported in different mouse studies that i.n. vaccination
with adjuvanted WIV  (Joo et al., 2010) or split viruses
(Ichinohe et al., 2005; Ichinohe et al., 2006; Saluja et al.,
2010) requires a boost vaccination for effective induction of
Ab. Furthermore, in chicken LPS-containing liposomal inac-
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Fig. 2. CT-B-speciﬁc Ab in serum of chickens aerosol-vaccinated with CT-
B  adjuvanted vaccine. The presence of CT-B-speciﬁc Ab in serum was
determined pre-vaccination, 1 wpv and 3 wpv. Data are shown as mean
OD ± SEM.
effective induction of serum IgG titers (Tseng et al., 2009).
As we already observed CT-B-speciﬁc antibodies in serum
at 1 wpv, the aerosol vaccination technique is in principle
feasible to use in a rapid intervention strategy. The num-
ber of HAU needed for protection was determined from
i.m. applied vaccine and therefore in a future experiment
we will increase the dose in order to determine the number
of HAU needed in a respiratory applied vaccine.
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